Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib With Dexamethasone as the First-line Treatment for Immunoglobulin Light Chain(AL) Amyloidosis

NCT02485613 is registered in ClinicalTrials.gov with Zhi-Hong Liu, M.D. as lead sponsor.

NCT NCT02485613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02485613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib With Dexamethasone as the First-line Treatment for Immunoglobulin Light Chain(AL) Amyloidosis
Lead sponsor
Zhi-Hong Liu, M.D.
Phase
Observational
Overall status
Completed
Start date
January 31, 2009
Completion date
March 31, 2015
Enrollment
72 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis